Tacrolimus vs placebo: Serious adverse events
- Population
- adults with refractory, moderate‐to‐severe ulcerative colitis
- Intervention
- Tacrolimus
- Comparison
- placebo
- Outcome
- Serious adverse events
It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Tacrolimus vs placebo Serious adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis It is very uncertain whether tacrolimus changes serious adverse events compared with placebo (very low certainty). Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis (2022) · Cochrane Headline outcomes only | RR 2.44 [0.12, 48.77] | 3 studies · 148 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Tacrolimus vs beclometasone · adults with refractory, moderate‐to‐severe ulcerative colitis · 1 review
- Tacrolimus vs ciclosporin · adults with refractory, moderate‐to‐severe ulcerative colitis · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.